Contrasting trajectories of heroin, cocaine, and methamphetamine use

Journal of Addictive Diseases

Volumn 27, Issue 3, 2008, Pages 13-21

  Hser, Yih Ing ^a   Huang, David ^a   Brecht, Mary Lynn ^a   Li, Libo ^a   Evans, Elizabeth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cocaine; Growth mixture model; Heroin; Methamphetamine; Trajectory

Indexed keywords

COCAINE; DIAMORPHINE; METHAMPHETAMINE;

ADULT; ARTICLE; COCAINE DEPENDENCE; CRIME; DRUG DEPENDENCE; DRUG USE; EXPERIMENTAL MODEL; FEMALE; HEALTH CARE POLICY; HEALTH PROGRAM; HEROIN DEPENDENCE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; METHAMPHETAMINE DEPENDENCE; POWDER; ADOLESCENT; CROSS-SECTIONAL STUDY; DRUG ABUSE; DRUG DEPENDENCE TREATMENT; ONSET AGE; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ADOLESCENT; ADULT; AGE OF ONSET; AMPHETAMINE-RELATED DISORDERS; CALIFORNIA; COCAINE-RELATED DISORDERS; CRIME; CROSS-SECTIONAL STUDIES; FEMALE; HEROIN DEPENDENCE; HUMANS; LONGITUDINAL STUDIES; MALE; METHAMPHETAMINE; SUBSTANCE ABUSE TREATMENT CENTERS; UTILIZATION REVIEW;

EID: 53049096091     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550880802122554     Document Type: Article

References (33)

1. http://www.ojp.usdoj.gov/bjs/abstract/cfjs04.htm.
2. http://ag.ca.gov/cjsc/publications/candd/cd05/preface.pdf.
3. https://dawninfo.samhsa.gov/default.asp.
4. http://oas.samhsa.gov/dasis.htm#teds2.
5. Compton WM, Glantz M, Delany P. Addiction as a chronic illness: Putting the concept into action. Eval Program Plann. 2003;26:353-4.
6. Hser Y, Longshore D, Anglin MD et al. The life course perspective on drug use: A conceptual framework for understanding drug use trajectories. Eval Rev. 31(6): 515-547.
7. McLellan AT. Have we evaluated addiction treatment correctly? Implications from a chronic care perspective. Addiction. 2002;97(3):249-52.
8. Hser Y, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58:503-08.
9. Muthen B. Latent variable analysis: Growth mixture modeling and related techniques for longitudinal data. In: Kaplan D, ed. Handbook of Quantitative Methodology for the Social Sciences.Thousand Oaks, CA: SAGE Publications; 2004:345-68.
10. Muthen B, Asparouhov T. Growth mixture analysis: Models with non-Gaussian random effects. Forthcoming In: Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G, eds. Advances in Longitudinal Data Analysis. Boca Raton, FL: Chapman & Hall/CRC Press; 2006.
11. Hser Y, Stark ME, Paredes A, Huang D, Anglin MD, Rawson R. A 12-year follow-up of a treated cocaine-dependent sample. J Subst Abuse Treat. 2006;30:219-26.
12. Brecht M, O'Brien A, Mayrhauser CV, Anglin MD. Methamphetamine use behaviors and gender differences. Addict Behav. 2004;29:89-106.
13. Hser Y, Huang D, Teruya C, Anglin MD. Diversity of drug abuse treatment utilization patterns and outcomes. Eval Program Plann. 2004;27:309-19.
14. Hser Y, Huang Y, Teruya C, Anglin MD. Gender differences in drug abuse treatment outcomes and correlates. Drug Alcohol Depend. 2003;72:255-64.
15. Nurco DN, Bonito AJ, Lerner M, Balter MB. Studying addicts over time: Methodology and preliminary findings. Am J Drug Alcohol Abuse. 1975;2:183-96.
16. McGlothlin WH, Anglin MD, Wilson BD. A follow-up of admissions to the California Civil Addict Program. Am J Drug Alcohol Abuse. 1977;4:179-99.
17. Hser Y, Anglin MD, Chou C. Reliability of retrospective self-report by narcotics addicts. Psychol Assess. 1992;4:207-13.
18. Chou C, Hser Y, Anglin MD. Pattern reliability of narcotics addicts' self-reported data: A confirmatory assessment of construct validity and consistency. Subst Use Misuse. 1996;31:1189-216.
19. Farrington DP. Developmental and life-course criminology: Key theoretical and empirical issues-The 2002 Sutherland award address. Criminology. 2003;2:221-56.
20. Muthen LK, Muthen BO. Mplus: Statistical Analysis with Latent Variables. User's Guide. 4th ed. Los Angeles, CA: Muthen & Muthen; 2006.
21. Anglin MD, Hser Y, Grella CE. Drug addiction and treatment careers among clients in the drug abuse treatment outcome study (DATOS). Psychol Addict Behav. Special Issue: Drug Abuse Treatment Outcome Study (DATOS). 1997;11:308-23.
22. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689-95.
23. Murray DW. Drug abuse treatment programs in the Federal Bureau of Prisons: Initiatives for the 1990s. In: Leukefeld CG,Tims FM, eds. Drug Abuse Treatment in Prisons And Jails (NIDA Research Monograph 118). Rockville, MD: National Institute on Drug Abuse; 1992:62-83.
24. Speckart G, Anglin MD. Narcotics use and crime: An overview of recent research advances. Contemp Drug Probl. 1986;13:741-69.
25. Anglin MD, Longshore D, Turner S. Treatment alternatives to street crime: An evaluation of five programs. Crim Justice Behav. 1999;26:168-95.
26. LongshoreD,UradaD,EvansE,Hser Y,Prendergast M, Hawken A. Evaluation of the Substance Abuse and Crime Prevention Act: 2004 Report. Los Angeles: UCLA Integrated Substance Abuse Programs; 2004.
27. Prendergast M, Huang D, Hser Y. Patterns of drug use and crime trajectories in relation to treatment initiation and five-year outcomes: An application of growth mixture modeling across three datasets. Eval Rev. 2007;32(1):59-82.
28. Moos R, Moos B. Protective resources and long-term recovery from alcohol use disorders. Drug Alcohol Depend. 2007;86(1):46-64.
29. Scott CK, Foss MA, Dennis ML. Factors influencing initial and longer-term responses to substance abuse treatment: A path analysis. Eval Program Plann. 2003;26:287-96.
30. McLellan AT. What if addiction were treated, evaluated and reimbursed as a chronic illness? Presented at: UCLA CALDAR Summer Institute on Longitudinal Research; August 26, 2006; Los Angeles, CA.
31. McKay JR. Is there a case for extended interventions for alcohol and drug use disorders? Addiction. 2005;100(11):1594-610.
32. Rush AJ, Koran LM, Keller MB, et al. The treatment of chronic depression, part 1. Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation and maintenance phase therapies. J Clin Psychiatry. 1998;59:589-97.
33. U.S. Dept. of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National Household Survey On Drug Abuse, 2000 [Computer file]. ICPSR03262-v4. Research Triangle Park, NC: Research Triangle Institute [producer], 2001. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2006-12-07.